tbuckley/cabot-search huggingface dataset:
Cardiovascular Magnetic Resonance in Acute ST-Segment–Elevation Myocardial Infarction
Authors: Heerajnarain Bulluck, Rohan Dharmakumar, Andrew E. Arai, Colin Berry, Derek J. Hausenloy
Journal: Circulation (2018)

Although mortality after ST-segment elevation myocardial infarction (MI) is on the decline, the number of patients developing heart failure as a result of MI is on the rise. Apart from timely reperfusion by primary percutaneous coronary intervention, there is currently no established therapy for reducing MI size. Thus, new cardioprotective therapies are required to improve clinical outcomes after ST-segment–elevation MI. Cardiovascular magnetic resonance has emerged as an important imaging modality for assessing the efficacy of novel therapies for reducing MI size and preventing subsequent adverse left ventricular remodeling. The recent availability of multiparametric mapping cardiovascular magnetic resonance imaging has provided new insights into the pathophysiology underlying myocardial edema, microvascular obstruction, intramyocardial hemorrhage, and changes in the remote myocardial interstitial space after ST-segment–elevation MI. In this article, we provide an overview of the recent advances in cardiovascular magnetic resonance imaging in reperfused patients with ST-segment–elevation MI, discuss the controversies surrounding its use, and explore future applications of cardiovascular magnetic resonance in this setting.
Universal health coverage: drug quality and affordability can go together
Authors: Raffaella Ravinetto, Catherine Dujardin
Journal: BMJ (2019)

In her thoughtful essay, Elizabeth Pisani warns against some possible unwanted consequences of the efforts to achieve universal health coverage.1 In particular, an unconditional push for the lowest possible prices of essential drugs may lead some manufacturers to apply cuts to quality assurance costs, thus increasing the risk of poor quality drugs or of manufacturers’ withdrawal from the market.1

The …
Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital
Authors: Angela Molga, Michelle Wall, Rakchha Chhetri, Amilia Wee, Deepak Singhal, Nimit Singhal, David M Ross, Luen Bik To, Peter G Bardy, Pratyush Giri, Gillian Caughey, Sepehr Shakib, Timothy To, Devendra K Hiwase
Journal: Blood (2018)
Increased Phosphatidylserine-Exposing Microparticles and Their Originating Cells Are Associated with the Coagulation Process in Patients with Oral Squamous Cell Carcinoma
Authors: Yingmiao Liu, Cong Zhang, Yan Kou, Lili Zou, Hui Liang, Li Hou, Tao Li, Yan Zhang, Baorong Li, Wenhui Liu, Nan Zuo, Jialan Shi, Tenglong Hu
Journal: Blood (2018)
Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An Inv(16)(p13.3;q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project
Authors: Tanja A Gruber, Amanda Larson Gedman, Huy Q. Ta, Jinghui Zhang, Cary Koss, Shann-Ching Chen, Xiaoping Su, Vedant Gupta, Stacey Ogden, Anna K. Andersson, John Easton, Jianmin Wang, Michael Rusch, Li Ding, Giovanni Cazzaniga, Andrea Biondi, Steven M. Kornblau, Farhad Ravandi, Hagop M. Kantarjian, Stephen D. Nimer, Konstanze Doehner, Hartmut Doehner, Timothy J Ley, Sheila Shurtleff, Jeffrey Rubnitz, Ching-Hon Pui, Elaine R. Mardis, Richard K. Wilson, James R. Downing
Journal: Blood (2011)
“Old boys club” culture at BMA undermined female members and staff, sexism report finds
Authors: Abi Rimmer
Journal: BMJ (2019)

A review into sexism at the BMA has found that the association has a discriminatory culture in which women were undermined, bullied, and in some instances sexually harassed.1

The independent review, by Daphne Romney QC, said that for too long BMA leadership had failed to call out bad behaviour, including sex discrimination, sexual harassment, rudeness, and bullying.

In gathering evidence, Romney said that she spoke in person to 82 men and women, over half of whom were female and a fifth of whom were members of staff. She said she also received emails from other doctors and members of staff.

Not everyone who spoke to Romney had experienced or witnessed sex discrimination or sexual harassment.

“I hope that this report will focus attention within the BMA on the damaging elements of its discriminatory culture, including the (limited) instances of sexual harassment,” Romney said.

“The latter is undoubtedly far more headline grabbing than the former, but that should not detract from the genuine complaints of the persistent undermining and undervaluing of some women doctors and staff, together with a corrosive and combative culture of ‘I’m right, and you’re wrong, and I know best, and you don’t know what …
Senescence Markers from a DLBCL-Reminiscent Mouse Lymphoma Model Predict Patient Outcome
Authors: Kolja Schleich, Julia Kase, Jan R. Dörr, Saskia Trescher, Animesh Battacharya, Yong Yu, Philipp Lohneis, Dido Lenze, Dorothy Ngo-Yin Fan, Michael Hummel, Ulf Leser, Clemens A. Schmitt
Journal: Blood (2018)
Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study
Authors: Mauricette Michallet, Mohamad Sobh, Marie Y. Detrait, Helene Labussiere, Sandrine Hayette, Isabelle Tigaud, Mohamed El Hamri, Lila Gilis, Fiorenza Barraco, Sophie Ducastelle, Valentina Bozzoli, Franck E. Nicolini, Xavier Thomas
Journal: Blood (2013)
Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies
Authors: Rui MA, Xiao-Jun Huang, Lan-Ping Xu, Kaiyan Liu, Xiaohui Zhang, Chen-Hua Yan, Wei Han, Feng-Rong Wang, Yu-Hong Chen, Huan Chen, Yao Chen, Jing-Zhi Wang, Yu Wang
Journal: Blood (2018)
Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
Authors: Kaijun Jin, Minjie Liu, Chunlin Zhuang, Erik De Clercq, Christophe Pannecouque, Ge Meng, Fener Chen
Journal: Acta Pharmaceutica Sinica B (2019)

In order to improve the positional adaptability of our previously reported naphthyl diaryltriazines (NP-DATAs), synthesis of a series of novel biphenyl-substituted diaryltriazines (BP-DATAs) with a flexible side chain attached at the C-6 position is presented. These compounds exhibited excellent potency against wild-type (WT) HIV-1 with EC50 values ranging from 2.6 to 39 nmol/L and most of them showed low nanomolar anti-viral potency against a panel of HIV-1 mutant strains. Compounds 5j and 6k had the best activity against WT, single and double HIV-1 mutants and reverse transcriptase (RT) enzyme comparable to two reference drugs (EFV and ETR) and our lead compound NP-DATA (1). Molecular modeling disclosed that the side chain at the C-6 position of DATAs occupied the entrance channel of the HIV-1 reverse transcriptase non-nucleoside binding pocket (NNIBP) attributing to the improved activity. The preliminary structure–activity relationship and PK profiles were also discussed.
Abstract 719: <i>CRISPR/Cas9-</i> Based Knockout of the <i>TLR4</i> gene Enhances Secretion of Extracellular Vesicles With Anti-Inflammatory Properties From Human Cardiac Mesenchymal Stromal Cells
Authors: Yeshai Schary, Nili Naftali-Shani, Jonathan Leor
Journal: Circulation Research (2019)

Background and Aim: The environment of the failing and infarcted myocardium drives resident and transplanted mesenchymal stromal cells (MSCs) toward a pro-inflammatory phenotype and restricts their survival and reparative effects in a mechanism mediated by the toll-like receptor 4 ( TLR4 ). CRISPR is a promising tool for genome editing of DNA in cells, which raises hope for therapeutic genome editing in the clinic. We hypothesize that ex-vivo knockout (KO) of the human TLR4 gene by CRISPR would switch human cardiac MSCs (hMSCs) to an anti-inflammatory, reparative phenotype that could prevent remodeling of the left ventricle after myocardial infarction (Fig. 1A). Methods and Results: For gene editing, we electroporated a Cas9 nucleoprotein aimed to KO the TLR4 gene. To assess the inflammatory response, we analyzed cell secretome. We achieved up to a 68% (out of 400,000 cells) success rate in editing the genome of hMSCs ( R 2 =0.93 ). The TLR4 KO hMSCs secreted smaller extracellular vesicles (sEVs) compared with unedited hMScs (Fig. 1B p&lt;0.001 ) and decreased the secretion of most pro-inflammatory (e.g. IL-1α) and pro-fibrotic (e.g. IL-10) cytokines from edited compared with unedited hMSCs (Fig. 1C, D). Additionally, sEVs from TLR4 KO cells stimulated hMSC migration by “wound healing” scratch assay ( p &lt; 0.001 ). Conclusion: Our preliminary results show, for the first time, that CRISPR-based KO of the human TLR4 gene in hMSCs inhibits inflammatory cytokine secretion and facilitates a reparative response by human-cardiac MSCs in vitro. The precise and efficient ex vivo gene editing could provide a newly engineered cell line to improve the outcome of hMSC-based cell therapy.
Adherence to clinical practice guidelines for the prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults with cancer receiving their first cycle of highly emetogenic chemotherapy.
Authors: Melissa Beauchemin, Chunhua Weng, L. Lee Dupuis, Lillian Sung, Dawn L. Hershman, Rebecca B. Schnall
Journal: Journal of Clinical Oncology (2019)

19 Background: Prescribing guideline-recommended anti-emetics for the prevention of chemotherapy-induced nausea and vomiting (CINV) is an effective strategy to prevent a common treatment-related adverse effect in children, adolescents and young adults (AYAs) with cancer that impacts quality of life. The rate of guideline-concordant care (GCC) is not well-understood. Methods: Using electronic health record data Columbia University Irving Medical Center from a 3-year period, we conducted a retrospective single-institution cohort study to investigate how often children and AYAs (age 26 or less) receive GCC to prevent CINV prior to the first administration of highly-emetogenic chemotherapy. We defined GCC from the Pediatric Oncology Group of Ontario guideline for patients &lt; 18 years and the American Society of Clinical Oncology guideline for those ≥ 18 years. Independent variables included: sex, age, insurance status, race, ethnicity, cancer type, chemotherapy regimen, clinical setting (adult or pediatric oncology), and patient location (inpatient or outpatient). Predictors of GCC were determined using multiple logistic regression. Results: Of 91 included patients, 39 (43%) received GCC. Those treated in adult oncology setting (OR 7.5, 95% CI: 2.7–20.7), receiving cisplatin-based chemotherapy (OR 3.5, CI: 1.4–8.5), or with commercial insurance (OR 2.7, CI: 1.1–6.3) were more likely to receive GCC. In multivariable analysis, patients treated in adult oncology had 6.4 higher odds (CI: 2.1–19.1, p&lt;.001) and those receiving cisplatin 4.6 higher odds (1.6–13, p&lt;.01) of GCC. Conclusions: Clinical setting and chemotherapy regimen independently predicted GCC for prevention of CINV in children and AYAs receiving highly-emetogenic chemotherapy. These findings can inform current efforts to optimize implementation strategies for supportive care guidelines by focusing on specific provider- and patient-level factors.
Hospice and medical oncology collaboration in a statewide collaborative.
Authors: Louise Bedard, Kelly Marie Procailo, Sam Beusterien, Kleanthe Kolizeras, Cindy Straight, Jennifer J. Griggs
Journal: Journal of Clinical Oncology (2019)

83 Background: Hospice enrollment (QOPI measure 42) has consistently been lower in practices in the Michigan Oncology Quality Consortium (MOQC), a collaborative of nearly all medical oncology practices. MOQC enrollment has been 47% during CY2014-18 compared to national QOPI, which ranged from 53 to 59% during the same time period. We describe our approach to improve hospice use in the care of oncology patients. Methods: MOQC providers suggested that hospices across the state be involved in facilitating patient-centered approaches to increase enrollment of patients to hospice care. Beginning in Spring 2018, hospices in each of the six MOQC regions were invited to participate in standing regional meetings as well as teleconferences (one per region). Root cause analyses identified barriers universal and specific to that region. Each region was asked to choose at least one hospice-oncology project. Results: Thirty hospices are participating, including the five largest hospices in the state and hospices associated with the largest healthcare systems. Barriers to hospice include lack of hospice services in rural areas, in complete understanding among oncologists about what hospice can provide, resistance from patients and families due to misperceptions, communication issues with oncologists, between practices and hospices, and/or with patients once referred to hospices, lack of appreciation by hospice providers regarding the long standing relationship between patients and oncologists, and variation in use of palliative treatment such as radiation therapy. A total of 13 projects have been selected by the hospices and oncology practices to be developed by the regions. Once harmonized by the Coordinating Center, the projects will be shared across the state. The Coordinating Center is addressing lack of access to hospice in remote rural areas. Conclusions: Our partnership between oncology practices and hospices across a statewide collaborative has been a mutually beneficial relationship that promises to address some of the key systemic barriers to hospice enrollment. Feedback has indicated that communication between oncology and hospice providers is becoming more seamless and that referrals to hospice have increased.
Comparison Of Intravenous With Oral Busulfan In Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimens For Pediatric Acute Leukemia
Authors: Motohiro Kato, Yoshiyuki Takahashi, Daisuke Tomizawa, Yasuhiro Okamoto, Jiro Inagaki, Katsuyoshi Koh, Atsushi Ogawa, Keiko Okada, Yuko Cho, Junko Takita, Hiroaki Goto, Hisashi Sakamaki, Hiromasa Yabe, Keisei Kawa, Ritsuro Suzuki, Kazuko Kudo, Koji Kato
Journal: Blood (2013)
Re-Analysis of Next Generation Sequencing Gene Panel Data By Normalized Coverage Values Reveals Previously Undetected Copy Number Variations in Inherited Bone Marrow Failure Syndromes
Authors: Supanun Lauhasurayotin, Iren Shabanova, Hongbing Li, Santhosh Dhanraj, Bozana Zlateska, Robert J Klaassen, Conrad Fernandez, Geoff De Cuvelier, John K. Wu, Yves D. Pastore, Mariana Silva, Jeffrey H. Lipton, Josee Brossard, Bruno Michon, Sharon Abish, MacGregor Steele, Roona Sinha, Mark J. Belletrutti, Vicky R. Breakey, Lawrence Jardine, Lisa Goodyear, Lillian Sung, Mary Shago, Michaela Cada, Scherer W Stephen, Yigal Dror
Journal: Blood (2017)
Patient experiences of care in localized prostate cancer.
Authors: Michelle Mollica, Lisa M Lines, Timothy S. McNeel, Serban Negoita, Sarah Gaillot, Marc Elliott, Michael T. Halpern, Ashley Wilder Smith, Elizabeth Siembida, Erin E Kent
Journal: Journal of Clinical Oncology (2019)

215 Background: Over 161,000 new prostate cancer patients diagnosed annually, with 75% diagnosed at early stages. Limited evidence exists supporting choice of treatment (including radical prostatectomy, radiation therapy, hormonal therapy, active surveillance or watchful waiting) for localized prostate cancer. Treatments have varying side effects associated with impaired functional status and health-related quality of life. Patient care experiences are important quality indicators, but research examining patient experiences by prostate cancer treatment is limited. The purpose of this study was to examine the association between treatment received (surgery, radiation, or no treatment) and CAHPS ratings of overall care over the prior six months. Methods: This study used data from SEER-CAHPS, which links Surveillance, Epidemiology, and End Results (SEER) data with Medicare Consumer Assessment of Healthcare Providers and Systems (CAHPS) patient experience survey and Medicare claims data. Medicare Fee-for-Service beneficiaries ≥65 years with a National Comprehensive Cancer Network (NCCN) low- or intermediate-risk prostate cancer diagnosis were assigned to surgery only, radiation only, and no treatment received groups for analysis. The outcome variable was a CAHPS rating of overall care (0 = worst; 10 = best). The analysis adjusted for case mix and other cancer-specific variables. Results: The final cohort included 507 prostate cancer survivors (surgery n = 109 [21%]; radiation n = 197 [39%]; no treatment n = 201 [40%]). Respondents who received radiation rated their overall care higher than those not receiving treatment (adjusted mean 8.9 vs 8.3; p= 0.02). Ratings did not differ significantly between the surgery and no treatment groups. Conclusions: This study represents a first look at patient experiences among localized prostate cancer survivors receiving surgery, radiation, or no treatment. It is not clear whether those who did not receive treatment chose active surveillance or watchful waiting, or whether they did not have access to care, which could have affected results. Future research should explore associations between receipt of treatment and patient care experiences in an adequately powered sample to inform future interventions.
Comorbidities Are Major Drivers of Overall Survival of Chronic Myelomonocytic Leukemia
Authors: Tyson Broadbent, Srinivas K. Tantravahi, Sowmya Ravulapati, Morgan Ward, Alexandra Asay, Ananth Peddinti, Isaac Kunz, Paul J Shami, Tibor Kovacsovics, Samir Courdy, Ken Boucher, Michael W. Deininger
Journal: Blood (2018)
Examining Oncotype DX testing among a diverse patient population in North Carolina.
Authors: Katie Marsh, Thad Benefield, Sheila Lee, Louise Henderson
Journal: Journal of Clinical Oncology (2019)

154 Background: The Oncotype DX (ODX) is a 21-gene assay that quantifies the risk of breast cancer recurrence and predicts chemotherapy benefit among early stage, hormone-receptor positive patients. Most major insurance carriers now cover testing. We sought to determine factors associated with ODX testing in a diverse patient population. Methods: Data from the Carolina Mammography Registry (CMR), a breast imaging registry in North Carolina (NC) was used for this analysis. We included women ages 18 and over diagnosed with breast cancer from 2010-2017 who had a breast imaging exam at a CMR facility with no personal history of breast cancer. ODX testing was obtained through linkage with the NC Central Cancer Registry. Using a backwards elimination selection strategy, we explored the association of patient residence (urban versus rural), age, race, breast density, and family history of breast cancer on receipt of ODX testing. Results: Our population included 12,329 breast cancers among women that were 24.2% non-white with a median age of 64 years (11.2% &lt; 50 years at time of diagnosis). The majority of our sample had dense breasts (52.0%), no family history of breast cancer (80.9%), and lived in urban areas (66.3%). Use of ODX testing increased from 15.7% in 2010 to 24.8% in 2017 (p-value for time trend &lt; 0.00001). Compared with white women, black women were less likely to receive ODX testing (aOR = 0.57; 95% CI: 0.51-0.65), as were women of other races (aOR = 0.68; 95% CI: 0.51-0.90). We found that for every year age increased, the likelihood of receiving ODX testing decreased (aOR = 0.98, 95% CI: 0.97-0.98). Patient residence and breast density influenced the association of ODX testing. Among women in urban areas, women with dense versus non-dense breasts were more likely to receive ODX testing (aOR = 1.13; 95% CI: 1.01-1.27). Among women in rural areas, density was not associated with ODX testing (aOR = 0.91; 95% CI: 0.78-1.06). Conclusions: In our cohort, ODX testing was more common among younger white women with dense breast tissue living in urban areas of NC. Additional research to understand differences in testing by rural/urban areas are warranted to ensure that all appropriate patients receive this genetic assay.
Computed tomography-guided additive manufacturing of Personalized Absorbable Gastrointestinal Stents for intestinal fistulae and perforations
Authors: Parinaz Fathi, Gweneviere Capron, Indu Tripathi, Santosh Misra, Fatemeh Ostadhossein, Laura Selmic, Blair Rowitz, Dipanjan Pan
Journal: Biomaterials (2019)
Whole-genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteraemia is caused by a limited number of closely related sequence types
Authors: S.A. Shelburne, R.W. Dib, B.T. Endres, R. Reitzel, X. Li, A. Kalia, P. Sahasrabhojane, A.-M. Chaftari, R. Hachem, N.S. Vargas-Cruz, Y. Jiang, K. Garey, V.G. Fowler, T.L. Holland, J. Gu, W. Miller, A. Sakurai, C.A. Arias, S.L. Aitken, D.E. Greenberg, J. Kim, A.R. Flores, I. Raad
Journal: Clinical Microbiology and Infection (2019)
A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups
Authors: Anna Ferrari, Silvia Vitali, Valentina Robustelli, Andrea Ghelli Luserna Di Rora, Simona Righi, Giovanni Pasquini, Cristina Papayannidis, Giovanni Marconi, Giulia Ferrari, Maria Chiara Fontana, Enrica Imbrogno, Eugenio Fonzi, Antonella Padella, Giorgia Simonetti, Alessandra Santoro, Jesús-María Hernández-Rivas, Michela Tebaldi, Samanta Salvi, Carmen Baldazzi, Maria Chiara Abbenante, Nicoletta Testoni, Massimiliano Bonafè, Castellani Gastone, Elena Sabattini, Michele Cavo, Daniel Remondini, Giovanni Martinelli
Journal: Blood (2018)
Rapid Molecular Detection of Pathogens in 516 Consecutive Haematological Patients with Febrile Neutropenia
Authors: Raffaella Greco, Maria Chiara Barbanti, Nicasio Mancini, Lara Crucitti, Alessandra Forcina, Francesca Lorentino, Alessia Orsini, Luca Vago, Fabio Giglio, Maria Teresa Lupo Stanghellini, Daniela Clerici, Matteo G Carrabba, Sarah Marktel, Andrea Assanelli, Magda Marcatti, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Massimo Clementi, Fabio Ciceri
Journal: Blood (2014)
Analysis of 12 Genes in 268 Cases with CMML Identifies ASXL1 Mutations As the Most Important Genetic Alteration Associated with Adverse Outcome
Authors: Susanne Schnittger, Manja Meggendorfer, Vera Grossmann, Tamara Alpermann, Christiane Eder, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood (2012)
Insights into the Molecular Mechanism Accounting for Neutropenia in T-Large Granular Lymphocytes Leukemia
Authors: Giulia Calabretto, Antonella Teramo, Barbara Mariotti, Marzia Rossato, Monica Castellucci, Gregorio Barilà, Matteo Leoncin, Cristina Vicenzetto, Vanessa Rebecca Gasparini, Monica Facco, Francesco Piazza, Gianpietro Semenzato, Flavia Bazzoni, Renato Zambello
Journal: Blood (2018)